# Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM

> **NCT06492330** · NA · COMPLETED · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 62 (actual)

## Conditions studied

- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Obesity
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** CS0159
- **DRUG:** CS0159 placebo

## Key facts

- **NCT ID:** NCT06492330
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-19
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-04-22
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06492330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06492330, "Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06492330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*